SCHEMBL5736871

SCHEMBL5736871

COC(=O)c1oc2ccc(Cl)cc2c1O

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.72
ALDH1A1 P00352 3/20 0.72
HPGD P15428 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
MAPK1 P28482 2/20 0.67
MCL1 Q07820 1/20 0.54
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 2/20 0.50
KCNH2 Q12809 1/20 0.49
TP53 P04637 1/20 0.49
HTT P42858 1/20 0.49
NQO1 P15559 1/20 0.49
CELA1 Q9UNI1 1/20 0.48
MAOB P27338 2/20 0.47
MGAM O43451 2/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
NR4A2 P43354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4782390 0.88 KDM4E (0.59) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL758464 0.84 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL4573629 0.84 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL25963177 0.83 KDM4E (0.50) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL25338376 0.82 KDM4E (0.49) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL5734812 0.82 KDM4E (0.72) KDM4EALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL5737276 0.81 MCL1 (0.69) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL4924288 0.80 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL11126153 0.80 KDM4E (0.71) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL17179764 0.78 CFTR (0.47) KDM4EALDH1A1HPGDSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171460-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF RIPARIAN PHARMACEUTICALS, INC. (US) 2025-05-29 US disclosed
EP-4476229-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF Riparian Pharmaceuticals, Inc. (US) 2024-12-18 EP disclosed
CN-118974057-A KLF2 inducers and methods of use thereof 里帕里安制药股份有限公司 2024-11-15 CN disclosed
WO-2023150374-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF RIPARIAN PHARMACEUTICALS, INC. (US) 2023-08-10 WO disclosed
WO-2023150374-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF RIPARIAN PHARMACEUTICALS, INC. (US) 2023-08-10 WO disclosed
EP-1644364-A1 TETRAZOL BENZOFURANCARBOXAMIDES WITH PI3K ACTIVITY AS THERAPEUTIC AGENTS Warner-Lambert Company LLC (US) 2006-04-12 EP disclosed
US-20050020631-A1 3-Substituted benzofurans as therapeutic agents GOGLIOTTI ROCCO DEAN (US) 2005-01-27 US disclosed
WO-2004108709-A1 TETRAZOL BENZOFURANCARBOXAMIDES WITH P13K AKTIVITY AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171460-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF SREBF2, LIPG, KLF5 KDM4E 999/4885ALDH1A1 1828/4885HPGD 662/4885
US-20050020631-A1 3-Substituted benzofurans as therapeutic agents CYP4F11, BPTF, F3 KDM4E 2213/4885ALDH1A1 103/4885HPGD 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.